A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [iodogen] dissolved in dimethyl sulphoxide (DMSO)

Xenobiotica

Volumn 43, Issue 8, 2013, Pages 730-737

  Cona, Marlein Miranda ^a   Li, Junjie ^a   Chen, Feng ^a   Feng, Yuanbo ^a   Alpizar, Yeranddy Aguiar ^b   Vanstapel, Florent ^c   Talavera, Karel ^b   De Witte, Peter ^c   Verbruggen, Alfons ^c   Sun, Ziping ^d   Oyen, Raymond ^a   Ni, Yicheng ^a,d  

^a DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^b LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Anticancer therapy; Formulation; Hypericin; Mice; Radioiodination

Indexed keywords

ALKALINE PHOSPHATASE; DIMETHYL SULFOXIDE; IODOGEN; OXIDIZING AGENT; UNCLASSIFIED DRUG; UREA;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART; HISTOPATHOLOGY; KIDNEY PARENCHYMA; LD 50; LIVER HISTOLOGY; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL; WEIGHT CHANGE;

ANIMALS; BODY WEIGHT; DIMETHYL SULFOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; LETHAL DOSE 50; MALE; MICE; ORGAN SPECIFICITY; OXIDATION-REDUCTION; SOLUBILITY; SURVIVAL ANALYSIS; UREA;

ANIMALIA; MUS;

EID: 84879926744     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.756559     Document Type: Article

References (25)

1. Caujolle FME, Caujolle DH. (1967). Limits of tolerance and teratogenic tolerance of dimethyl sulfoxide. Ann NY Acad Sci 141:110-25.
2. Cheung WMW, Ng WW, Kung AW. (2006). Dimethyl sulfoxide as an inducer of differentiation in preosteoblast MC3T3-E1 cells. FEBS Lett 580:121-6.
3. Council Chemical-Biological Coordination Center. (1953). Summary tables of biological tests. Washington (DC): National Research Council Chemical-Biological Coordination Center, National Academy of Science Library, Vol. 5:339.
4. Duchene D. (1991). New trends in cyclodextrins and derivatives. Paris: Editions de Sante.
5. Evans JM, Latto IP, Ng WS. (1974). Accidental intra-arterial injection of drugs: a hazard of arterial cannulation: 3 case reports. Br J Anaesth 46:463-6.
6. Fabry ME, Costantini F, Pachnis A, et al. (1992). High expression of human bs- and a-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci USA 89:12155-9.
7. Fonge H, Jin L, Wang H, et al. (2008a). Synthesis and preliminary biological evaluation of a 99mTc-labeled hypericin derivative as a necrosis avid imaging agent. J Label Compd Radiopharm 51:33-40.
8. Fonge H, Vunckx K, Wang H, et al. (2008b). Noninvasive detection and quantification of acute myocardial infarction in rabbits using mono- [123I]iodohypericin mSPECT. Eur Heart J 29:260-9.
9. Katholieke Universiteit Leuven-Oncocidia (2012). Available from: http://vimeo.com/44871398 [last accessed 12 Oct 2012].
10. Kelada E, Jones A. (2007). Interstitial cystitis. Arch Gynecol Obstet 275:223-9.
11. Kubin A, Meissner P, Wierrani F, et al. (2008). Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to polyvinylpyrrolidone: PVP-hypericin. Photochem Photobiol 84:1560-3.
12. Li J, Cona MM, Feng YB, et al. (2012). A single-dose toxicity study in mice on non-radioactive iodinated hypericin for a targeted anticancer therapy. Acta Pharmacol Sin 33:1549-56.
13. Li J, Sun Z, Zhang J, et al. (2011). A new anticancer approach based on the soil-and-seeds principle. Radiology 260:799-807.
14. Litchfield J, Wilcoxon F. (1949). A simplified method of evaluating dose effect experiments. J Pharmacol Exp Ther 96:99-113.
15. Ni Y, Huyghe D, Verbeke K, et al. (2006). First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 33:595-601.
16. Ni Y, van de Putte M, de Witte P, et al. (2012). European patent EP2219683B1: Targeted radiotherapy.
17. Sgarbossa A, Angelini N, Gioffré D, et al. (2000). The uptake, location and fluorescence of hypericin in bovine intact lens. Curr Eye Res 21:597-601.
18. Sgarbossa A, Lenci F. (2001). Spectroscopic study of visible-light effects on hypericin-lens proteins systems. Photochem Photobiol 74:196-200.
19. Stephens AS, Stephens SR, Hobbs C, et al. (2011). Myocyte enhancer factor 2c: an osteoblast transcription factor identified by DMSOenhanced mineralization. J Biol Chem 286:30071-86.
20. Sun ZP, Ni Y. (2009). Patent CN 200910013998: Iodogen method for preparation of radioiodinated Hypericin.
21. Tallarida RJ, Murray RB. (1987). Manual of pharmacological calculations with computer programs. 2nd ed. New York: Springer, 59-63.
22. Unak T, Akgün Z, Yildirim Y, et al. (2001). Self-radioiodination of iodogen. Appl Radiat Isot 54:749-52.
23. van de Putte M, Roskams T, Bormans G, et al. (2006). The impact of aggregation on the biodistribution of hypericin. Int J Oncol 28:655-60.
24. Walker M. (1993). DMSO: nature's healer. Garden City Park (NY): Avery Publishing Group Inc., 61-3.
25. Willson JE, Brown DE, Timmens EK. (1965). A toxicologic study of dimethyl sulfoxide. Toxicol Appl Pharmacol 1:104-12.